<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932123</url>
  </required_header>
  <id_info>
    <org_study_id>2019_EOS_001</org_study_id>
    <nct_id>NCT03932123</nct_id>
  </id_info>
  <brief_title>Antibiotic Therapy for Early Onset Neonatal Sepsis</brief_title>
  <official_title>Efficacy and Safety of Antibiotics in the Treatment of Early Onset Neonatal Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Central Hospital of Gynecology Obstetrics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic therapy for early onset neonatal sepsis recommended by international guidelines
      and relevant studies is only kind of treatment regimen that penicillin G/
      penicillin/ampicillin combined with gentamicin as the first-line treatment regimen. However,
      it is not applicable to the clinical practice in many countries and regions. We aim to study
      efficacy and safety of antibiotics in the treatment of early onset neonatal sepsis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>72 hours after ending initial antibiotic therapy</time_frame>
    <description>requiring additional courses of antibiotic therapy within 72 hours after ending initial antibiotic therapy and/or
progression of the illness, necessitating a change of antibiotic and/or
blood culture isolate reported resistant to the antibiotic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>Duration of initial antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>In the first month of patients' life</time_frame>
    <description>Duration of hospitalization of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD target</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>The time of free drug concentration exceeding the minimal inhibitory concentration (fT&gt;MIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>White blood cell count in ×10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>Procalcitonin in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>C-reactive protein in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>In the first month of patients' life</time_frame>
    <description>Death in the first month of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>Drug-related adverse events and serious adverse events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Early Onset Neonatal Sepsis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin</intervention_name>
    <description>Efficacy and safety of antibiotics</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neonates suffered from early onset neonatal sepsis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: postnatal age ≤ 72h;

          -  Meets NICE guidelines for using antibiotics to treat EONS;

          -  Azlocillin used as part of antimicrobial treatment;

          -  Parental written consent.

        Exclusion Criteria:

          -  Expected survival time less than the treatment cycle;

          -  Major congenital malformations;

          -  Undergoing surgery within the first week of life;

          -  Receiving other systemic trial drug therapy;

          -  Other factors that the researcher considers unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Zhao, Ph.D</last_name>
    <phone>86053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Central Hospital of Gynecology Obstetrics</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>30000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuying Tian, bachelor</last_name>
      <phone>022-58287230</phone>
      <email>txyjk2008@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiuying Tian, bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Azlocillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

